Yu Waye Chu
About Yu Waye Chu
Yu Waye Chu serves as the Chief Medical Officer at CytomX Therapeutics, where he has been since 2023. He possesses extensive experience in clinical development, particularly in pediatric hematology-oncology and immunology, and has contributed to numerous drug development initiatives throughout his career.
Work at CytomX Therapeutics
Yu Waye Chu serves as the Chief Medical Officer at CytomX Therapeutics, a position he has held since 2023. Based in South San Francisco, California, he operates in a hybrid work environment. In this role, he is responsible for overseeing clinical development strategies and the execution of clinical trials, contributing to the company's mission in advancing innovative cancer therapies.
Previous Roles at Fate Therapeutics Inc
Prior to joining CytomX Therapeutics, Yu Waye Chu held several key positions at Fate Therapeutics Inc. He served as Senior Vice President of Clinical Development from 2020 to 2022, and as Chief Medical Officer from 2022 to 2023. His tenure at Fate Therapeutics included responsibilities in clinical development and strategic oversight of oncology-focused biopharmaceuticals.
Education and Expertise
Yu Waye Chu earned his medical degree with Distinction in Research from the University of Rochester School of Medicine and Dentistry, completing his studies from 1991 to 1996. He also holds a Bachelor of Arts in Molecular Biology from Princeton University, which he obtained from 1985 to 1989. His educational background supports his extensive clinical expertise in pediatric hematology-oncology, immunology, and hematopoietic stem cell transplantation.
Clinical Experience and Research Background
Yu Waye Chu has a robust clinical background, having worked at the National Cancer Institute in various capacities, including Attending Physician in the Pediatric Oncology Branch and Assistant Clinical Investigator in the Experimental Transplantation and Immunology Branch. His experience spans over a decade in clinical research and patient care, focusing on pediatric oncology and immunology.
Achievements in Drug Development
Throughout his career, Yu Waye Chu has been involved in the initiation and execution of Phase I through Phase III studies and NDA filings. He has extensive experience in the development of antibody drug conjugates, antibody-based cancer immunotherapies, and engineered immune cell therapies. His work includes both early and late-stage drug development, as well as participation in clinical trial collaborations and strategic partnerships with major pharmaceutical companies.